OrganiGram Holdings Inc.

TSX:OGI.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.96 -1.43%

-$0.02 today

Market cap
$135.37M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $1.37High $3.09

Volume 0.54M

Average 0.19M

OGI.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

OrganiGram Holdings Inc.TSX: OGI.TO

Research & Development · Q2 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q2 FY2026 research & development of CA$2.03M fell 23.9% year over year, behind the +9.4% change in trailing-twelve-month research & development. Sequentially, it fell 2.8% from the prior quarter.

Context

  • Research & development amounted to 4.2% of revenue in FY2025, down 2.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -23.9% toward the trailing-twelve-month pace of +9.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$2.03M-2.8% QoQ
Last fiscal yearSep 2025
CA$10.95M-2.3% YoY
LTMMar 2026
CA$10.02M+9.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.9%——
1 year-2.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
10.95M CAD
Year-over-year change
-2.3%
4-year CAGR
+33.5%

Research & Development vs competitors

How OGI.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.4% is the 4th highest of 6, against a peer median of +31.9%.
  • Research & development amounts to 3.7% of revenue for OGI.TO, versus a peer median of 0.0%.
OGI.TO Competitors
Research & Development for OGI.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.07M USD+139.8%+7.0%—
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$10.02M CAD+9.4%—3.7%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$4.85M CAD+31.9%-15.1%1.5%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$267K CAD+62.8%—0.2%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$205.18K USD-48.4%-58.4%0.4%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-39.8%0.0%
DR.TOMedical Facilities CorporationLTM Mar 2026$0 USD——0.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$0 USD——0.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding OGI.TO) —+31.9%-27.4%0.0%

Competitors are the stored peer set for OGI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue79.16M145.81M149.21M159.84M259.18M
Cost of Revenue107.56M114.24M114.13M112.32M249.67M
Gross Profit(28.4M)31.57M35.07M47.52M9.51M
Gross Margin-35.9%21.7%23.5%29.7%3.7%
Research & Development3.45M5.96M12.19M11.2M10.95M
Selling, General & Admin46.52M59.21M71.68M68.14M86.88M
Operating Expenses63.42M70.32M277.81M83.2M97.82M
Depreciation & Amortization31.03M24.91M24.17M12.08M17.98M
EBITDA(95.59M)10.97M(207.62M)(23.59M)(20.55M)
EBITDA Margin-120.8%7.5%-139.2%-14.8%-7.9%
Operating Income(91.82M)(43.15M)(242.74M)(35.67M)(88.31M)
Operating Margin-116.0%-29.6%-162.7%-22.3%-34.1%
Interest Income003.69M3.31M1.15M
Interest Expense2.96M429K277.85K00
Other Income / Expenses(38.88M)28.78M9.74M(9.77M)49.78M
Income Before Tax(130.7M)(14.37M)(233M)(45.44M)(38.53M)
Pre-Tax Margin-165.1%-9.9%-156.2%-28.4%-14.9%
Income Tax Expense0(88K)(3.52M)(5.28M)(13.77M)
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Net Margin-165.1%-9.8%-153.8%-28.4%-9.6%
EPS (Basic)(2.04)(0.18)(2.82)(0.48)(0.19)
EPS (Diluted)(2.04)(0.18)(2.82)(0.48)(0.19)
Weighted Avg Shares64.03M77.23M81.29M95.29M127.67M
Weighted Avg Shares (Diluted)64.03M77.23M81.29M95.29M127.67M

OrganiGram Holdings Inc.

TSX:OGI.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.